TrovaGene Signs Deal with NerPharMa

Biotechnology company TrovaGene has executed a supplier agreement with pharmaceutical manufacturing company NerPharMa to manufacture drug product for PCM-075. The agreement covers the clinical and commercial supply of PCM-075 for Trovagene, and includes both Active Pharmaceutical Ingredients (API) and GMP (Good Manufacturing Process) production of capsules.

Under the terms of the deal, Trovagene directs NerPharMa to produce GMP-grade PCM-075 drug substance for use in Trovagene’s phase 1b/2 clinical program and for other related clinical and commercial activities. Trovagene is developing PCM-075, a polo-like kinase 1 (PLK1) inhibitor, and plans to initiate a phase 1b/2 clinical trial in patients with acute myeloid leukemia.

By Bucky Rini